Elizabeth Warren wants Gilead CEO Daniel O'Day in the hot seat to talk drug pricing and competitiveness

Zachary Brennan

Senior Editor

Given Gilead’s experience in developing storied new drugs for hepatitis C and Covid-19, and marketing them with hefty price tags, Massachusetts Sen. Elizabeth Warren …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Elizabeth Warren wants Gilead CEO Daniel O'Day in the hot seat to talk drug pricing and competitiveness

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Eliz­a­beth War­ren wants Gilead CEO Daniel O'­Day in the hot seat to talk drug pric­ing and com­pet­i­tive­ness

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Elizabeth Warren wants Gilead CEO Daniel O'Day in the hot seat to talk drug pricing and competitiveness